Mimicking the action of Sex Hormone Binding Globulin (SHBG) effectively reduces ectopic fat, fibrosis and inflammation. Endolipid Tx is developing two novel peptides with validated efficacy - in vivo PoC: EDL6D for NASH and EDL3D for Cellulite/Slimming.
NASH is a growing and underserved disease. Endolipid Tx is developing EDL6D, an in vivo effective peptide that may offer a treatment opportunity for NASH with a novel and differentiated mechanism of action.
Cellulite and Slimming are poorly attended pathologies with scarce therapeutic innovation in the last 10 years. Endolipid Tx is developing EDL81, a peptide with a innovative mode of action and proven in vitro and in vivo efficacy in reducing ectopic fat in Cellulite and Slimming.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Passeig De La Vall D’hebron 119-129, Barcelona , Spain, Barcelona,barcelona 08035,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://endolipid.com/
- HQ
- Barcelona, Barcelona
Endolipid Therapeutics Questions
Endolipid Therapeutics's website is https://endolipid.com/
Endolipid Therapeutics's LinkedIn profile is https://es.linkedin.com/company/endolipid-therapeutics
Endolipid Therapeutics has
3 employees.
View email and phone details for 3
employees at Endolipid Therapeutics.
Endolipid Therapeutics's industry is
Biotechnology Research
Endolipid Therapeutics's top competitors are
Tecnologia Regenerativa Qrem,
Santero Therapeutics,
Telara Pharma,
Devshealth,
Pharmamar,
Imidomics Inc.,
Ownmed Innovation,
Polar Nanopharma,
Abac Therapeutics,
Airway Shield.
Endolipid Therapeutics's categories are Biotechnology Research
Endolipid Therapeutics's founding year is 2021
